Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 12;90(6):431–444. doi: 10.1007/s00280-022-04483-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — GNE987's anti-tumor activity is closely related to VHL expression. a Identification of VHL overexpression or knockdown by Western blotting in GBM cells. b Identification of VHL overexpression or knockdown by RT-qPCR in GBM cells. c Effects of VHL overexpression or knockdown on cell viability after treatment of GBM cells with GNE987. d Schematic diagram of the targeted degradation of BRD4 by GNE987; GNE987 binds both BRD4 and a VHL E3-ubiquitin ligase complex. Formation of the trimeric complex results in the transfer of ubiquitin to BRD4. e Western blotting of BRD in U87 and LN229 cells treated with GNE987, MG132 and their combination. (Data were presented with mean ± SD of three independent experiments, *P < 0.05, **P < 0.01, ***P < 0.001)